kabutan

Nxera Pharma hits third milestone in AbbVie neuroscience collaboration

Mon Apr 20, 2026 3:54 pm JST Catalyst

NXERA PHARMA CO., LTD. <4565> announced after the market close it has hit the third research-stage milestone in its drug discovery collaboration with AbbVie for neurological disorders. As a result, Nxera will receive $10 million. It plans to recognize the majority of the payment as revenue in FY2026, with the remainder to be recognized in fiscal 2027 and beyond.

Under the drug discovery and option license agreement signed with AbbVie in 2022, Nxera is entitled to up to $40 million in early development milestones. Additionally, Nxera could receive up to $1.2 billion in milestones upon option exercise and achievement of development and commercial targets, plus tiered royalties based on global sales.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles